1. PERKENI. Pengelolaan dan pencegahan diabetes mellitus tipe 2 di Indonesia. Jakarta: PB Perkeni. 2021 https://pbperkeni.or.id/wp-content/uploads/2021/11/22-10-21-Website-Pedoman-Pengelolaan-dan-Pencegahan-DMT2-Ebook.pdf
2. Rodriguez-Gutierrez R, Gonzales JG, Zuniga-Hernandez JA. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019;367:l5887 http://dx.doi.org/10.1136/bmj.l5887
3. Herrera-Gómez F, Asensio-González M, González-López A, et al. Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. Front Pharmacol 2017;8:845. doi:10.3389/ fphar.2017.00845
4. Lind M, Pivodic A, Svensson AM, Ólafsdóttir AF, Wedel H, Ludvigsson J. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ. 2019 Aug 28;366:l4894. doi: 10.1136/bmj.l4894.
5. American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, et al. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S83-S96. doi: 10.2337/dc22-S006.
6. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008;358:2560-72
7. Pantalone KM, Misra-Hebert AD, Hobbs TM, et al. Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes. J Diabetes. 2018 Mar;10(3):192-199. doi: 10.1111/1753-0407.12613.
8. Rodríguez-Gutiérrez R, Montori VM. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):504-12. doi: 10.1161/CIRCOUTCOMES.116.002901.
9. Tian J, Ohkuma T, Cooper M, et al. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial. Diabetes Care. 2020 Jun;43(6):1293-1299. doi: 10.2337/dc19-1817.
10. Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA 2016;315:1034-45. doi:10.1001/jama.2016.0299
11. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 2014;174:1227-34. doi:10.1001/jamainternmed.2014.2894
12. Davis HA, Spanakis EK, Cryer PE, et al. Hypoglycemia During Therapy of Diabetes. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. 2021 https://www.ncbi.nlm.nih.gov/books/NBK279100/